Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Simple Summary The diagnosis and prediction of prognosis for bladder cancer (BC) can be
challenging because of the subjective nature of pathological evaluation. Artificial …

Urinary extracellular vesicles (uEVs) are regarded as highly promising liquid-biopsy
biomarkers for the early diagnosis and prognosis of bladder cancer (BC). However …

AI holds strong potential to guide decision-making for BC diagnosis and treatment and to
integrate such models into the current clinical workflow. This review summarizes the …

Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer
(mUC) for more than two decades. However, many patients with comorbidities cannot …

The treatment of metastatic urothelial carcinoma has dramatically changed over the past
decade with the approval of several therapies from multiple drug classes including immune …

With the improvement of implant design and the expansion of application scenarios,
orthopedic implants have become a common surgical option for treating fractures and end …

Activating FGFR3 alterations have been identified in up to 15–20% of muscle-invasive
bladder cancer and metastatic urothelial carcinoma (mUC), and as high as 80% in …

We aimed to investigate the genomic and tumor microenvironmental (TME) profiles in non-
muscle invasive bladder cancer (NMIBC) and explore potential predictive markers for …

Cisplatin-based chemotherapy is currently the first-line standard of care for patients with
metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for …